Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Turn Therapeutics Inc.NASDAQ: TTRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income of -$970.97K in Q1 FY2026
Q1 FY2026 net income was -$970.97K. Trailing-twelve-month net income was -$3.84M.
Context
- Net income grew in size in 1 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$1.37M (-57.0%) for the fiscal year ending Dec 2026, a slowdown from the +80.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$970.97K-447.9% QoQ
- Last fiscal yearDec 2025
- -$3.19M+80.6% YoY
- LTMMar 2026
- -$3.84M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | -52.5% | — |
| 1 year | +80.6% | -57.0% | -137.6 pp |
| 3-year CAGR | — | -9.9% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (3.19M) USD
- Year-over-year change
- -80.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.19M) | -80.6% |
| FY2024 | 2024-12-31 | (1.77M) | +22.9% |
| FY2023 | 2023-12-31 | (2.29M) | — |
Net Income vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 net income of $3.84M is the smallest of the 9 companies compared; the peer median is $26.34M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $50.96M | +39.4% | +38.8% | — | |
| LTM Mar 2026 | $30.92M | — | +47.5% | — | |
| LTM Mar 2026 | $21.76M | +31.3% | +35.2% | — | |
| LTM Mar 2026 | $19.58M | -41.2% | +3.2% | — | |
| LTM Apr 2026 | $10.1M | -17.6% | -7.1% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.84M | — | — | — |
| Peer median (excluding TTRX) | $26.34M | +31.3% | +3.2% | 468.7% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 640.26K | 352.83K | 419.25K |
| Change in Working Capital | 229.74K | (1.86K) | 2.37M |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 2.26M |
| Other Working Capital | 229.74K | (1.86K) | 105.03K |
| Other Non-Cash Items | 662 | 8.65K | (2.21M) |
| Operating Cash Flow | (1.38M) | (1.36M) | (2.56M) |
| Capital Expenditures | (44.31K) | (99.48K) | (152.99K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (152.99K) |
| Investing Cash Flow | (44.31K) | (99.48K) | (152.99K) |
| Debt Repayment | 0 | 0 | 0 |
| Common Stock Issued | 500K | 1.15M | 6.92M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 500K | 1.15M | 6.92M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (921.99K) | (308.4K) | 4.2M |
| Free Cash Flow | (1.42M) | (1.46M) | (2.72M) |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.